At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,981 enrolled
Drug / intervention
Epirubicin: Observational Studydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer ((ANWENDUNGSBEOBACHTUNG,MOI 99056 -Neo-/Adjuvante Chemotherapie Des Primären Mammakarzinoms Der Frau Mit Farmorubicin®))
In Brief
An observational study evaluating Epirubicin: Observational Study for Breast Neoplasm. Completed, enrolled 1,981 participants.
Detailed Summary
Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) / C(600mg). Evaluation of unexpected and serious adverse events. (E=Epirubicin; C =Cyclophosphamide)
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasm
Countries--
Collaborators--
Timeline
N/ACompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 1999
Primary CompletionOct 2009
First PostedFeb 2010
TodayJul 2026
First PostedFeb 3, 2010
Enrollment StartJan 1, 1999
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10.8 yearsPosted 16.4 years ago
Interventions
Epirubicin: Observational Studydrug
Observational: Chemotherapy